Part 1

DRUG4 trials

Sponsors

Bausch & Lomb Incorporated, Daewoong Pharmaceutical Co. LTD., Sun Pharma Advanced Research Company Limited, Harmony Biosciences Management, Inc.

Conditions

Advanced Breast CancerAnaphylaxisDrug InteractionHER2-negative Breast CancerHormone Receptor-positive Breast CancerMild to Moderate COVID-19

Phase 1

Study to Explore the Pharmacokinetics and Pharmacodynamics of Epinephrine in Healthy Male and Female Subjects With Different Skin to Muscle Depth (STMD)

CompletedNCT03282929

Bausch & Lomb IncorporatedAnaphylaxis

Start: 2017-03-23End: 2018-10-15Updated: 2019-06-21

A Study in Patients With Advanced Breast Cancer

TerminatedNCT04942054

Sun Pharma Advanced Research Company LimitedAdvanced Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor-positive Breast Cancer

Start: 2022-05-20End: 2023-02-28Updated: 2023-05-22

Drug Interaction Study of ZYN002 Transdermal Gel and Probe Substrates

CompletedNCT06930872

Harmony Biosciences Management, Inc.Drug Interaction

Start: 2025-06-06End: 2025-11-04Updated: 2026-02-09

Phase 2

Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19 Compared to the Placebo

TerminatedNCT04521296

Daewoong Pharmaceutical Co. LTD.Mild to Moderate COVID-19

Start: 2020-09-11End: 2022-03-18Updated: 2022-06-15

Related Papers

A Double-Blind, Randomized, Placebo-Controlled, Phase II Clinical Study To Evaluate the Efficacy and Safety of Camostat Mesylate (DWJ1248) in Adult Patients with Mild to Moderate COVID-19.

2022-12-1418 citations